SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, has appointment a new vice president of quality. The company announced that Wm. Dewey Rushing will be serving as SOHM vice president for quality. Rushing has been serving on the company’s advisory board member and that experience combined with his impressive background in management and leadership make him ideally qualified for his new role. A well-known expert in the field of pharmaceutical quality validation and cGMP compliance, Rushing has a resume that includes cell therapy IND readiness, quality systems audits, aseptic processing, cGMP compliance and regulation, along with process validation and transfer. He brings invaluable insights and expertise to his new role and will be integral as the company diversifies its portfolio with new products and expands to new markets. “Wm. Dewey Rushing is a senior compliance remediation and quality professional with more than 30 years of experience in quality assurance and cGMP compliance for FDA-regulated products,” said SOHM president and CEO Baron Night in the press release. “He joined SOHM’s advisory board last year and has been providing his expertise on validation and compliance issues. SOHM has appointed him as the vice president of quality, recognizing his exceptional qualifications and experience in pharmaceutical quality validation and cGMP compliance.”
To view the full press release, visit https://ibn.fm/qTEzd
About SOHM Inc.
SOHM is a growing generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that aims to build continuous growth. SOHM manufacturing and marketing targets rapidly growing healthcare segments such as nutraceuticals, cosmeceuticals and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India and strategic alliances with U.S. manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and were introduced to the United States in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America and Southeast Asia. For more information about the company, please visit www.SOHM.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
